A nationwide, multicenter retrospective study on the effectiveness and safety of eribulin in Korean breast cancer patients (REMARK)
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Min Ho | - |
dc.contributor.author | Lee, Soo Jung | - |
dc.contributor.author | Noh, Woo Chul | - |
dc.contributor.author | Jeon, Chang Wan | - |
dc.contributor.author | Lee, Seok Won | - |
dc.contributor.author | Son, Gil Soo | - |
dc.contributor.author | Moon, Byung-In | - |
dc.contributor.author | Lee, Jin Sun | - |
dc.contributor.author | Kang, Sung Soo | - |
dc.contributor.author | Suh, Young Jin | - |
dc.contributor.author | Gwak, Geumhee | - |
dc.contributor.author | Kim, Tae Hyun | - |
dc.contributor.author | Yoo, Young Bum | - |
dc.contributor.author | Kim, Hyun-Ah | - |
dc.contributor.author | Kim, Min Young | - |
dc.contributor.author | Kim, Ju Yeon | - |
dc.contributor.author | Jeong, Joon | - |
dc.date.accessioned | 2021-08-30T06:12:56Z | - |
dc.date.available | 2021-08-30T06:12:56Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2020-12 | - |
dc.identifier.issn | 0960-9776 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/50903 | - |
dc.description.abstract | Purpose: Approval of eribulin for metastatic breast cancer was based on data primarily from Western patients, and there is a paucity of data on the effectiveness and safety of eribulin for Asian patients. To determine the effectiveness and safety of eribulin in Korean women with breast cancer in a real-world setting, we conducted a nationwide, multicenter, retrospective study. Methods: Patients with locally advanced or metastatic breast cancer who were treated with eribulin in 14 centers throughout Korea were included in this study. Eribulin was generally administered at a dose of 1.23 mg/m(2) (equivalent to 1.4 mg/m(2) eribulin mesylate) by intravenous infusion for 2-5 min, or as a diluted solution, on Days 1 and 8 of every 21-day cycle. The primary endpoint was progression-free survival (PFS) rate at 6 months. Secondary endpoints included median PFS, overall survival (OS), time-to-treatment failure (TTF), tumor response rate, and incidence of hematologic treatment-emergent adverse events (TEAEs). Results: The safety and full analysis populations included 398 and 360 (38 had no efficacy data) patients, respectively. The PFS rate at 6 months was 37.8%. Median PFS, OS, and TTF were 134, 631, and 120 days, respectively. Objective response rate, clinical benefit rate, and disease control rate were 18.1%, 50.6%, and 49.4%, respectively. Hematologic TEAEs were reported in 65.1% of patients; neutropenia (56.8%) and anemia (11.3%) were most common. Conclusion: Real-world effectiveness and safety of eribulin in Korean breast cancer patients were consistent with previous reports; no new safety concerns were identified. (C) 2020 The Author(s). Published by Elsevier Ltd. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | CHURCHILL LIVINGSTONE | - |
dc.subject | OPEN-LABEL | - |
dc.subject | CAPECITABINE | - |
dc.subject | MESYLATE | - |
dc.subject | PHASE-3 | - |
dc.subject | WOMEN | - |
dc.title | A nationwide, multicenter retrospective study on the effectiveness and safety of eribulin in Korean breast cancer patients (REMARK) | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Son, Gil Soo | - |
dc.identifier.doi | 10.1016/j.breast.2020.09.004 | - |
dc.identifier.scopusid | 2-s2.0-85091503408 | - |
dc.identifier.wosid | 000604437000018 | - |
dc.identifier.bibliographicCitation | BREAST, v.54, pp.121 - 126 | - |
dc.relation.isPartOf | BREAST | - |
dc.citation.title | BREAST | - |
dc.citation.volume | 54 | - |
dc.citation.startPage | 121 | - |
dc.citation.endPage | 126 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Obstetrics & Gynecology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Obstetrics & Gynecology | - |
dc.subject.keywordPlus | OPEN-LABEL | - |
dc.subject.keywordPlus | CAPECITABINE | - |
dc.subject.keywordPlus | MESYLATE | - |
dc.subject.keywordPlus | PHASE-3 | - |
dc.subject.keywordPlus | WOMEN | - |
dc.subject.keywordAuthor | Eribulin mesylate | - |
dc.subject.keywordAuthor | Breast cancer | - |
dc.subject.keywordAuthor | Retrospective study | - |
dc.subject.keywordAuthor | Korean patients | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.